BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Papastergiou V, Karatapanis S. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 2015; 3(3): 210-220 [PMID: 25789294 DOI: 10.12998/wjcc.v3.i3.210]
URL: https://www.wjgnet.com/1007-9327/full/v3/i3/210.htm
Number Citing Articles
1
André F. Santos, Gonzalo Bello, Luãnna L. Vidal, Suiane L. Souza, Daiana Mir, Marcelo A. Soares. In-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 proteaseScientific Reports 2016; 6(1) doi: 10.1038/srep31780
2
A. Ferreira-Gonzalez. Diagnostic Molecular Pathology2017; : 485 doi: 10.1016/B978-0-12-800886-7.00038-8
3
Nghia H. Nguyen, Mindie H. Nguyen. Current Treatment Options in Patients with Hepatitis C Virus Genotype 6Gastroenterology Clinics of North America 2015; 44(4): 871 doi: 10.1016/j.gtc.2015.07.010
4
Simona Ruta, Costin Cernescu. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypesWorld Journal of Gastroenterology 2015; 21(38): 10811-10823 doi: 10.3748/wjg.v21.i38.10811
5
Winnie de Bruijn, Cristina Ibáñez, Pia Frisk, Hanne Bak Pedersen, Ali Alkan, Patricia Vella Bonanno, Ljiljana S. Brkičić, Anna Bucsics, Guillaume Dedet, Jaran Eriksen, Joseph O. Fadare, Jurij Fürst, Gisselle Gallego, Isabella P. Godói, Augusto A. Guerra Júnior, Hakkı Gürsöz, Saira Jan, Jan Jones, Roberta Joppi, Saim Kerman, Ott Laius, Newman Madzikwa, Einar Magnússon, Mojca Maticic, Vanda Markovic-Pekovic, Amos Massele, Olayinka Ogunleye, Aisling O'Leary, Jutta Piessnegger, Catherine Sermet, Steven Simoens, Celda Tiroyakgosi, Ilse Truter, Magnus Thyberg, Kristina Tomekova, Magdalena Wladysiuk, Sotiris Vandoros, Elif H. Vural, Corinne Zara, Brian Godman. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureFrontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00197
6
Tawhida Y Abdel-Ghaffar, Mostafa M Sira, Suzan El Naghi. Hepatitis C genotype 4: The past, present, and futureWorld Journal of Hepatology 2015; 7(28): 2792-2810 doi: 10.4254/wjh.v7.i28.2792
7
Samar F. Darwish, Wesam M. El-Bakly, Reem N. El-Naga, Azza S. Awad, Ebtehal El-Demerdash. Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapyBiochemical Pharmacology 2015; 98(1): 231 doi: 10.1016/j.bcp.2015.09.001
8
Aoran Luo, Pan Xu, Jin Wang, Zuli Li, Shunli Wang, Xiaoyan Jiang, Hong Ren, Qiang Luo. Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6Medicine 2019; 98(20): e15626 doi: 10.1097/MD.0000000000015626
9
José A. Morales-Molina, Jesús M. Fernández-Martín, Joaquín Urda-Romacho, Diana González-Vaquero, Alba Martos-Rosa. Clinical Management of Cirrhotic Patient With HCV Genotype 5 Treated With Simeprevir, Sofosbuvir, and RibavirinAnnals of Pharmacotherapy 2016; 50(9): 788 doi: 10.1177/1060028016653408
10
Al-Shazly Gaber Mohamed Galal, Reham M. Dawood, Mostafa K. El Awady, Yasser Mohamed Mohamed El-Dessouky, Mohamed Mahmoud Abdel-Halim Mahmoud, Mohamed Darwish Ahmed Abd Alla. Recognition of 7 genes signature (Cirrhosis Risk Score) in the diagnosed non-responders to DAAs therapy by intra-PBMCs nested HCV RNA PCRJournal of Genetic Engineering and Biotechnology 2023; 21(1): 89 doi: 10.1186/s43141-023-00544-3